No Data
No Data
shandong buchang pharmaceuticals (603858.SH): Proposed cancellation of controlling subsidiary Shangzhi Bucang Biology
Shandong Buchang Pharmaceuticals (603858.SH) announced that Shangzhi Buchang Medical Technology Co., Ltd. (referred to as 'Shangzhi Buchang Bio') is a wholly-owned subsidiary of the company. Based on the current operational situation and future business development plans, the company has decided to deregister Shangzhi Buchang Bio in order to optimize resource allocation and organizational structure, reduce management costs, and improve operational efficiency.
Even Though Shandong Buchang Pharmaceuticals (SHSE:603858) Has Lost CN¥1.2b Market Cap in Last 7 Days, Shareholders Are Still up 1.2% Over 5 Years
Shandong Buchang Pharmaceuticals (603858.SH): has repurchased 3.03% of the shares.
As of September 18, 2024, Shandong Buchang Pharmaceuticals (603858.SH) announced that the company has repurchased a total of 33,555,543 shares through centralized bidding trading method, accounting for 3.03% of the total share capital of the company. The highest repurchase price was 17.44 yuan/share, and the lowest price was 14.16 yuan/share. The total amount paid so far is 527,869,189.62 yuan (excluding transaction costs). The proportion of repurchased shares has rounding errors.
Here's Why Shandong Buchang Pharmaceuticals (SHSE:603858) Has A Meaningful Debt Burden
Shandong Buchang Pharmaceuticals (603858.SH): plans to donate pharmaceuticals and cash totaling 37.6621 million yuan for public welfare activities.
On September 13th, BuChang Pharmaceuticals (603858.SH) announced that the company, along with its wholly-owned subsidiary Shandong BuChang Pharmaceuticals Sales Co., Ltd. and its holding subsidiary Liaoning Ouda Pharmaceuticals Co., Ltd., has signed donation agreements with relevant public institutions to donate pharmaceuticals and cash totaling 37.6621 million yuan for charitable activities.
Buchang Pharma Unit Gets Nod to Market Fasudil Hydrochloride Injection
No Data
No Data